![](https://news.europawire.eu/wp-content/uploads/2023/08/bayer-BlueRock-Therapeutics-bit.bio_-144x144.jpg)
(IN BRIEF) BlueRock Therapeutics and bit.bio have announced a collaboration and option agreement to discover and manufacture iPSC-derived regulatory T cells (Tregs) for therapeutic use. Tregs are crucial for immune system balance and controlling excessive immune reactions, making them potential … Read the full press release